{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:13:10Z","timestamp":1788268390507,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacig.2026.100679","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:17:38Z","timestamp":1773159458000},"page":"100679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities"],"prefix":"10.1016","volume":"5","author":[{"given":"Triaji Suryo Condro","family":"Widagdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3401-7782","authenticated-orcid":false,"given":"Deasy","family":"Fetarayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wita Kartika","family":"Nurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Baskoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gatot","family":"Soegiarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100679_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/biomedicines13010163","article-title":"Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus-host disease in individuals with chronic myeloid leukemia: a retrospective analysis on behalf of the polish adult leukemia group","volume":"13","author":"Giordano","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacig.2026.100679_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jacig.2026.100679_bib3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2021.2020321","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemia","volume":"56","author":"Kwon","year":"2021","journal-title":"Blood Res"},{"key":"10.1016\/j.jacig.2026.100679_bib4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacig.2026.100679_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00439-025-02745-x","article-title":"Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration","volume":"144","author":"Sutanto","year":"2025","journal-title":"Hum Genet"},{"key":"10.1016\/j.jacig.2026.100679_bib6","first-page":"367","article-title":"Sensorineural hearing loss in juvenile CML: a rare case report in Surabaya, Indonesia","volume":"15","author":"Syamsuddin","year":"2022","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.jacig.2026.100679_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jacig.2026.100679_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17512433.2021.1894129","article-title":"Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies","volume":"14","author":"Wang","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacig.2026.100679_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2017.10.004","article-title":"Akt activation: a potential strategy to ameliorate insulin resistance","volume":"156","author":"Zhang","year":"2019","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932600041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932600041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:13:22Z","timestamp":1788264802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277282932600041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S277282932600041X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100679","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100679"}}